UnknownPhase 2/3

MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment

China120 participantsStarted 2014-09

Plain-language summary

The purpose of this study is to compare the efficacy of mesenchymal stem cells (MSCs) with or without granulocyte colony-stimulating factor (G-CSF) mobilized peripheral stem cells (PBSC) in treating patients experiencing poor graft function or delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation.

Who can participate

Age range14 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age：14-65 years * PGF or DPE after allo-HSCT * Subjects (or their legally acceptable representatives) must have signed an informed consent document Exclusion Criteria: * Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * Patients with any conditions not suitable for the trial (investigators' decision)

What they're measuring

Percentage of Participants with Hematopoietic Recovery

Timeframe: 1 year

Trial details

NCT IDNCT02240992

SponsorNanfang Hospital, Southern Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-09

Contact for this trial

Ren Lin, MD

+86-020-62787883 lansinglinren@hotmail.com

View on ClinicalTrials.gov More Stem Cell Transplantation, Hematopoietic trials